Organon & Co. (OGN) Stock Price & Analysis
Organon & Co. (OGN) closed at USD 13.75 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 13.75; the Oct 22, 2026 session ranged USD 13.74–13.76 on volume of 2,553,567 shares. Market capitalization is $3.61B, with a 52-week range of USD 5.69–13.83 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:50 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OGN.md
Key facts (OGN)
- Last four reported quarters (through Jun 30, 2026): revenue $6.13B, net income $209M (3.4% margin), free cash flow $567M (SEC filings).
- Valuation: P/E 17.3x (avg 6.0x at the last 3 fiscal year-ends), net debt $7.42B.
- 1 of 80 tracked superinvestors hold OGN (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $200K; 1 not under a Rule 10b5-1 plan ($200K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $353K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 3.40 on a 1–5 scale) (5 analysts), mean target USD 11.25 (range 8–14).
- Total return with dividends: 1Y +53.2% vs S&P 500 +14.9%; 5Y -53.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD 0.94, revenue estimate $1.58B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OGN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.30B | $6.17B | $6.26B | $6.40B | $6.22B | $6.13B |
| Gross profit | $3.92B | $3.88B | $3.75B | $3.71B | $3.31B | — |
| Net income | $1.35B | $917M | $1.02B | $864M | $187M | $209M |
| EPS (diluted) | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 | — |
| Free cash flow | $1.97B | $662M | $548M | $764M | $538M | $567M |
| Gross margin | 62.2% | 62.8% | 59.8% | 58.0% | 53.3% | — |
| Net margin | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% | 3.4% |
| Revenue growth | -3.5% | -2.1% | +1.4% | +2.2% | -2.9% | — |
| Cash + short-term investments | $737M | $706M | $693M | $675M | $574M | — |
| Total debt | $9.13B | $8.91B | $8.76B | $8.88B | $8.64B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OGN)
P/E 17.3x · P/S 0.6x · EV/Sales 1.8x · P/FCF 6.4x · P/B 3.6x · FCF yield 15.70% · Earnings yield 5.79% · Dividend yield (paid, TTM) 0.50% · Net debt $7.42B · EV $11.0B
P/E at fiscal year-ends: Dec 2025 10.0x, Dec 2024 4.5x, Dec 2023 3.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (OGN)
1 of 80 tracked investors hold OGN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Kahn Brothers | Kahn Brothers Group | 5.88% | $33.2M | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (OGN)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-05 | Drinane Juliana Papa | Head of Mfg & Supply | 14,761 | $200K | 44.4% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (OGN)
1 purchase, $353K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-06 | Holzbaur Lynette | SVP and Corporate Controller | 26,448 | $353K | 13.35 | Too little history (no open-market trades in 2023–2025) |
Analysts (OGN)
Consensus Hold (mean 3.40 on a 1–5 scale), 5 analysts; mean target USD 11.25 (low 8, high 14).
Total return (dividends reinvested) (OGN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +53.2% | -53.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +53.4% | -14.0% |
| Volatility (annualized) | 62.5% | 45.6% |
| Max drawdown | -41.5% (Jan 2026→Mar 2026) | -82.2% (May 2022→Mar 2026) |
OGN revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Nexplanon/Implanon NXT | $230.0M | 14.8% | -4.2% |
| Zetia | $96.0M | 6.2% | +29.7% |
| Other | $96.0M | 6.2% | +10.3% |
| Atozet | $80.0M | 5.1% | -7.0% |
| Hadlima | $79.0M | 5.1% | +58.0% |
| Other Non-Opiod Pain, Bone and Dermatology | $79.0M | 5.1% | -1.2% |
| Arcoxia | $69.0M | 4.4% | +9.5% |
| Renflexis | $65.0M | 4.2% | +3.2% |
| Follistim AQ | $59.0M | 3.8% | -20.3% |
| Nasonex | $58.0M | 3.7% | -12.1% |
| Emgality | $54.0M | 3.5% | +28.6% |
| Cozaar/Hyzaar | $50.0M | 3.2% | -10.7% |
| Singulair | $48.0M | 3.1% | -27.3% |
| Other Women's Health | $45.0M | 2.9% | +7.1% |
| Diprospan | $44.0M | 2.8% | +7.3% |
| Dulera | $41.0M | 2.6% | +0.0% |
| Propecia | $36.0M | 2.3% | +12.5% |
| Vtama | $35.0M | 2.2% | +12.9% |
| Marvelon/Mercilon | $32.0M | 2.1% | -3.0% |
| Clarinex | $30.0M | 1.9% | -11.8% |
| NuvaRing | $27.0M | 1.7% | -3.6% |
| Ganirelix Acetate Injection | $26.0M | 1.7% | -3.7% |
| Other Cardiovascular | $25.0M | 1.6% | -26.5% |
| Fosamax | $25.0M | 1.6% | -26.5% |
| Vytorin | $21.0M | 1.3% | -22.2% |
| Proscar | $20.0M | 1.3% | -9.1% |
| Bildyos/Bilprevda | $19.0M | 1.2% | — |
| Other Respiratory | $18.0M | 1.2% | +28.6% |
| Brenzys | $14.0M | 0.9% | -36.4% |
| Other | $14.0M | 0.9% | -39.1% |
| Other Biosimilars | $12.0M | 0.8% | +71.4% |
| Ontruzant | $6.0M | 0.4% | -80.6% |
| Rosuzet | $5.0M | 0.3% | -16.7% |
| Total revenue | $1.56B | 100% | — |
OGN revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Int’l | $1.16B | 74.5% | -1.7% |
| — Europe and Canada (part of Int’l) | $432.0M | 27.7% | +3.1% |
| — Latin America, Middle East, Russia, and Africa (part of Int’l) | $269.0M | 17.3% | -5.6% |
| — Asia Pacific and Japan (part of Int’l) | $232.0M | 14.9% | -7.2% |
| — China (part of Int’l) | $208.0M | 13.4% | +2.0% |
| — Other (part of Int’l) | $19.0M | 1.2% | -13.6% |
| U.S. | $398.0M | 25.5% | -3.9% |
| Total revenue | $1.56B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
OGN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Merck (MRK) | “We also manufacture and package a range of products for third parties, including Merck & Co., Inc. ("Merck") at each of our six manufacturing sites pursuant to third-party contract manufacturing agreements.” |
| Supplier | Samsung Bioepis | “•We rely on our commercialization agreements with Samsung Bioepis, Henlius and Biothera for the successful development and manufacture of our biosimilars products and expect to do so for the foreseeable future.” |
| Supplier | Shanghai Henlius Biotech | “•We rely on our commercialization agreements with Samsung Bioepis, Henlius and Biothera for the successful development and manufacture of our biosimilars products and expect to do so for the foreseeable future.” |
| Partner | Eli Lilly (LLY) | “We are party to a distribution agreement with Eli Lilly ("Lilly") for Emgality, a humanized monoclonal antibody calcitonin gene-related peptide ("CGRP") antagonist, that is indicated for the preventive treatment of migraine in adults, and in some markets, the indication specifies prophylaxis for those with at least four migraine days per month.” |
| Partner | Claria Medical | “In 2023, we made a strategic investment in Claria Medical, Inc. ("Claria").” |
| Partner | BIOGEN INC. (BIIB) | “Under the terms of the agreement with Biogen, we paid an upfront payment of $51 million in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solutions Ltd., the product developer for Tofidence.” |
| Partner | Samsung Electronics | “For further information related to the Samsung Bioepis collaboration, see Note 16 "Samsung Collaboration" to the Consolidated Financial Statements included in this 2025 Form 10-K and the Samsung Bioepis Agreement, which is filed as an exhibit to this 2025 Form 10-K.” |
| Partner | Bio-Thera Solutions | “Under the terms of the agreement with Biogen, we paid an upfront payment of $51 million in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solutions Ltd., the product developer for Tofidence.” |
Quoted from the company's 10-K filed Feb 24, 2026.
OGN company outlook (results filed Apr 30, 2026)
- “The merger is expected to close in early 2027, subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders. ·”
- “In the U.S., sales of Nexplanon declined 28% primarily due to both decreased physician demand following the five-year label approval which as expected, has delayed reinsertions; and continued uncertainty around federal funding.”
- “Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the merger, including the anticipated timing of completion thereof.”
Quoted word-for-word from the SEC 8-K results press release.
OGN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.94 | $1.05 | -10.5% | $1.58B | 4 |
| Next quarter (ends Dec 2026) | $0.67 | $0.66 | +2.8% | $1.55B | 4 |
| Current fiscal year (ends Dec 2026) | $3.42 | $3.62 | -5.6% | $6.17B | 6 |
| Next fiscal year (ends Dec 2027) | $3.62 | $3.64 | -0.6% | $6.32B | 6 |
OGN options: expected move
Options price a move of about ±3.3% (±$0.45) by Dec 18, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±7.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Dec 18, 2026 | 56 | 24.8% | ±3.3% |
| Jan 15, 2027 | 84 | 27.4% | ±10.2% |
30-day implied volatility 9.6% vs 2.8% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:50 UTC)
| Price | USD 13.75 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 13.75 |
| Open | USD 13.75 |
| Day Range | USD 13.74 – 13.76 |
| 52-Week Range | USD 5.69 – 13.83 |
| Volume | 2,553,567 shares |
| Market Cap | $3.61B |
| Exchange | NYQ |
Technical Analysis (OGN)
Nexqual's technical model rates OGN "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:50 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 48.46 (neutral) |
| vs SMA50 | Above (USD 13.73) |
| MACD | 0.01 (positive) |
Analyst Ratings (OGN)
Wall Street analysts rate OGN "Hold" based on 5 analysts, with a mean price target of USD 11.25 (range USD 8–14), per Nexqual as of October 23, 2026 at 09:50 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11.25 |
| High Target | USD 14 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 0 / 4 / 1 |
Earnings (OGN)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 0.94 |
| Revenue Estimate | $1.58B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.85 vs est 1.07 ▼ miss |
| 2026-03-31 | USD 0.71 vs est 0.85 ▼ miss |
| 2025-12-31 | USD 0.63 vs est 0.73 ▼ miss |
| 2025-09-30 | USD 1.01 vs est 0.93 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:50 UTC.
Financials & Fundamentals (OGN)
| Total Revenue | $6.13B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -2.30% |
| Gross Margin | +53.40% |
| Operating Margin | +20.73% |
| Profit Margin | +3.41% |
| ROE | +24.04% |
| Debt / Equity | 8.5 |
| Current Ratio | 1.95 |
| Total Cash | $1.13B |
| Total Debt | $8.55B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $567.00M (9.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:50 UTC.
Financial Health Score (OGN)
Nexqual rates Organon & Co.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:50 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 53%, operating 21% (last 12 months) |
| Balance Sheet | Critical — $1.13B cash and investments vs $8.55B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $567M (last 4 quarters to Jun 2026, SEC), 9% margin |
| Efficiency | Strong — ROE 24%, ROA 5.7% |
Ownership (OGN)
| Insider Ownership | +0.46% |
|---|---|
| Institutional Ownership | +84.60% |
| Shares Outstanding | 262.61M |
| Float | 243.05M |
| Short % of Float | +8.21% |
Source: Nexqual, October 23, 2026 at 09:50 UTC.
Leadership (OGN)
Organon & Co. is led by Joseph T. Morrissey, Chief Executive Officer, per Nexqual as of October 23, 2026 at 09:50 UTC.
| Chief Executive Officer | Joseph T. Morrissey |
|---|---|
| Executive VP & CFO | Matthew M. Walsh C.F.A. |
| Chief Strategy Officer & Head of Corporate Development | Daniel Karp |
Major Backers & Investors (OGN)
Notable institutional backers of Organon & Co. include Pentwater Capital Management Lp, Goldman Sachs, UBS Group AG, according to Nexqual as of October 23, 2026 at 09:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pentwater Capital Management Lp | 6.89% |
| Goldman Sachs | 1.98% |
| UBS Group AG | 1.85% |
| Alliancebernstein L.P. | 1.81% |
| Man Group PLC | 1.59% |
| NexPoint Funds I-NexPoint Merger Arbitrage Fund | 1.03% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.21% |
| Vanguard Group | 10.3% |
| State Street | 3.68% |
| Geode Capital | 1.83% |
Source: Nexqual, October 23, 2026 at 09:50 UTC.
From Organon & Co.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration ("FDA"), and the Company is assessing the future commercial launch of this product. •Established Brands: We have a portfolio of established brands, which includes brands in cardiovascular, respiratory, dermatology and non-opioid pain management, including Emgality®2 (galcanezumab-gnlm) and Vtama® (tapinarof) cream 1%.
- In 2025, this portfolio contributed approximately $3.7 billion, or approximately 59% of our total revenues, with approximately 91%, or $3.4 billion, generated outside the United States.
- The Centers for Medicare & Medicaid Services ("CMS") has taken steps to implement the IRA, including, most notably, releasing the Maximum Fair Prices, which will be effective in 2026 and 2027, for the drugs that were selected as part of the first two rounds of the Medicare Drug Price Negotiation Program and releasing quarterly lists of Medicare Part B products that are subject to adjusted coinsurance rates based on the inflationary rebate provisions of the IRA.
- We operate on a global scale through a global network that enables us to distribute products to patients in more than 140 countries and territories, with approximately 74% of our 2025 revenues, or $4.6 billion, generated outside the United States.
Partnerships
- Xaciato® (clindamycin phosphate) vaginal gel is an FDA-approved medication for the treatment of BV in females 12 years of age and older, which is licensed through an agreement with Daré Biosciences.
- On July 27, 2022, we entered into a research collaboration and exclusive license agreement with Cirqle Biomedical ("Cirqle") that entitled us to exclusive worldwide rights to develop and commercialize the product.
Legal & Regulatory Risks (Item 1A, quoted)
- Changes in tax laws or other tax guidance could adversely affect our effective tax rates, financial condition or results of operations.
- The completion of the self-initiated Audit Committee (as defined below) internal investigation and the subsequent implementation of our remediation plan has been time-consuming and expensive and may result in significant additional expense and/or litigation.
- We may be unable to market our pharmaceutical products or medical devices if we do not obtain and maintain required regulatory approvals or marketing authorizations.
- We are subject to a variety of laws and regulations, and we may face serious consequences for violations if we fail to meet the applicable legal and regulatory requirements.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GRFS | Grifols, S.A. | USD 7.45 | ▼ 0.67% |
| BIIB | Biogen Inc. | USD 253.84 | ▲ 5.34% |
| SNY | Sanofi | USD 41.96 | ▲ 2.42% |
| GSK | GSK plc | USD 51.21 | ▲ 2.38% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:50 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt